SciBX
Science-Business eXchange

THE DISTILLERY

## This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|---|---|---|---|---|
| **Cardiovascular disease** | | | | |
| Ischemia/ reperfusion injury | MicroRNA-27a (miR-27a); *VE-cadherin* (*CD144*; *cadherin-5*) | Mouse studies suggesting blocking the interaction between miR-27a and *VE-cadherin* transcripts could help treat ischemia. In a mouse model of hind limb ischemia, an RNA antagomir that inhibits the miR-27a-*VE-cadherin* interaction decreased edema and increased both blood flow and angiogenesis in ischemic muscle compared with a control antagomir. Next steps include evaluating the blockade of the miR-27a-*VE-cadherin* interaction in other arterial injury models and determining the therapeutic window for use of the antagomir.<br>Mirrx Therapeutics A/S has an IP stake in the blockmir antagomir technology used in this work and is developing blockmirs for therapeutic and research use.<br><br>*SciBX* 6(40); doi:10.1038/scibx.2013.1125<br>Published online Oct. 17, 2013 | Patent pending covering use in indications related to vascular edema; available for licensing from Bio-Link Australia Pty. Ltd. | Young, J.A. *et al. Blood*; published online Sept. 5, 2013; doi:10.1182/blood-2012-12-473017<br>**Contact:** Jennifer R. Gamble, The University of Sydney, Sydney, New South Wales, Australia<br>e-mail: j.gamble@centenary.org.au |